HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Desenex Max Supported With Comparative TV Ads, FSIs

This article was originally published in The Tan Sheet

Executive Summary

The "triple-strength" of Desenex Max compared to other available OTC athlete's foot remedies is emphasized in promotions accompanying the launch of Novartis' new terbinafine hydrochloride 1% cream.

You may also be interested in...



Novartis Lamisil One-Week Cure Ad Claims Substantiated - NAD

Novartis Consumer Health's Lamisil AT "cures with just one week's use" advertising claim for the treatment of athlete's foot is not likely to mislead consumers, the National Advertising Division of the Council of Better Business Bureaus determined.

Novartis Lamisil AT OTC Antifungal Said To Work In One Week

Novartis said its new OTC athlete's foot medication Lamisil AT Cream is the only nonprescription medication that cures athlete's foot with one week of treatment in its announcement that FDA has approved the Rx-to-OTC switch.

Novartis Backing Revamped Desenex Antifungals With $7.5 Mil.

Novartis Consumer Health is streamlining and repackaging its Desenex athlete's foot care line to consist of only prescription-strength products; the firm is phasing out the regular strength items.

Topics

UsernamePublicRestriction

Register

RS133055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel